Eton Pharmaceuticals, Inc. - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2026 Annual Meeting of Stockholders held virtually on June 9, 2026. The filing details the outcomes of shareholder votes regarding director elections and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
No material financial changes are reported in this filing. The primary events are the election of two new directors and the ratification of the external auditor.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future financial performance. It reports the following specific governance outcomes:
- Director Elections: Stockholders elected Jenn Adams and Charles J. Casamento to three-year terms.
- Auditor Ratification: Stockholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the year ending December 31, 2026.
Key Facts for Investor Verification
- Director Jenn Adams: Received 13,370,948 votes "For" and 2,149,317 "Withheld".
- Director Charles J. Casamento: Received 9,925,548 votes "For" and 5,594,717 "Withheld".
- Auditor Ratification: Received 16,942,328 votes "For", 3,236,671 "Against", and 5,301 "Abstain".
- Broker Non-Votes: 4,664,035 broker non-votes were recorded for the director election proposals.